Supported by an educational grant from Quest Diagnostics
Inflammatory arthritides comprise a variety of chronic progressive diseases that can cause irreversible joint damage early in the disease course. A large proportion of patients with inflammatory arthritis are first seen in the primary care setting, where they present initially before a diagnosis has been made. Early diagnosis and treatment of rheumatoid arthritis (RA) is important in preventing long-term damage and disability. Although RA is suspected largely on the basis of clinical findings such as persistent joint pain, swelling, and stiffness, laboratory investigations can contribute to an early diagnosis. This program will focus on the importance of early identification of RA and the proper use and interpretation of laboratory tests in order to provide patients with timely referrals and early treatment initiation.
This activity is intended for primary care physicians, internists, and rheumatologists.
After participating in this activity, clinicians should be better able to:
Differentiate rheumatoid arthritis (RA) from noninflammatory arthritides and appropriately diagnose patients using evidence-based assessment and diagnostic tools
Discuss the importance of early diagnosis and management of RA for optimal treatment and improved patient outcomes
Utilize and interpret laboratory tests and findings to detect and distinguish inflammatory arthritis
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Disclosures are as follows: The staff, planners, managers, and reviewer at Haymarket Medical Education have no relevant financial relationships to disclose.
Chair Martin J. Bergman, MD, FACR, FACP Chief, Division of Rheumatology Taylor Hospital Clinical Associate Professor of Medicine, Division of Rheumatology Drexel University College of Medicine Philadelphia, PA
Dr. Bergman is a consultant for AbbVie, Bristol-Myers Squibb, Celgene Corporation, Genentech/Roche, Janssen Pharmaceuticals, Amgen, Pfizer, and Quest Diagnostics. He is also on the speakers’ bureaus for AbbVie and Celgene Corporation and has an ownership interest in Merck, Pfizer, Johnson & Johnson, and Bristol-Myers Squibb.
Paul P. Doghramji, MD, FAAFP Family Physician, Collegeville Family Practice Pottstown Medical Specialists, Inc. Collegeville, PA
Dr. Doghramji is a consultant for Iroko Pharmaceuticals and is on the speakers’ bureaus for Takeda, Teva Pharmaceuticals, and Merck & Co., Inc.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only those credit commensurate with the extent of their participation in the activity.
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all post-test questions, completed the post-test survey, and received your digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
Disclosure of Unlabeled Use
This educational activity may contain discussion of unapproved and/or investigational uses of agents that are not indicated by the FDA. Haymarket Medical Education and Quest Diagnostics do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Quest Diagnostics. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.